(UroToday.com) The Plenary agenda of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting included a session, entitled “So Your Patient with Kidney or Bladder Cancer Responded to Immunotherapy: What’s Next?”. In this context, Dr. Mamta Parikh from UC Davis Comprehensive Cancer Center discussed considerations for the treatment of patients who respond well to immunotherapy and are on therapy for a long time.